6th Edition of Global Conference on
Addiction Medicine, Behavioral Health and Psychiatry
October 20-22, 2025 | Orlando, Florida, USA
Naloxone
It is an opioid antagonist, which means that it inhibits or reverses the effects of opioid medications. It is mostly used to treat opioid drug overdoses due to its antagonistic properties. Naloxone binds to albumin at a rate of around 45%, although it also strongly interacts with other proteins. In order to stop the effects of opioid drugs, naloxone temporarily inhibits opioid receptors. Because naloxone cannot be used to get high, there is minimal risk that it will be taken without a prescription. There is no evidence that long-term naloxone use can have harmful physiological effects or cause dependence. Users of naloxone do not develop tolerance, and the drug is not known to have contributed to any overdose deaths. This condition primarily affects people in their 20s and 30s. The prodromal phase refers to the time before symptoms appear.
Nile Stanley
University of North Florida, United States
Ann Marie Leonard Zabel
Curry College, United States
Denis Larrivee
University of Navarra, Spain
Scharbach Hugues
Paris University, France
Alphonsus Obayuwana
Triple-H Project LLC, United States
Malasri Chaudhery Malgeri
Recovery com, United States
Jana Furstova
Palacký University Olomouc, Czech RepublicSubmit your abstract Today
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States